Core Technology

Cellid Co.,Ltd. leads development of anti-cancer immunotherapy.

Original CeliVax Technology

Antigen Gene

Tumor antigen genes are delivered to autologous B cells and monocytes using a replication-defective recombinant adenoviral vector.
Tumor antigen expressing B cells and monocytes can activate immune responses that kill target cancer cells.

Scroll left and right to read.

  • Tumor antigens for target cancer indications are carefully selected and validated.
  • The selected tumor antigen genes are delivered to autologous B cells and monocytes.
  • Cellid’s own recombinant adenoviral vector maximizes tumor antigen gene delivery.